Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Tango Therapeutics Inc. — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $76.76 (market cap $17.41B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 4.7× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 61 Days and Tango Therapeutics Inc. for 0 Days on average.
| HYG | TNGX | |
|---|---|---|
Market Cap | $17.41B | $3.74B |
Volume | 63,579,674 | 3,438,781 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $32.90 |
52-Week Low | $76.81 | $7.50 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.09, down 0.26% amid a bearish technical signal with moving averages indicating selling pressure. The ETF shows neutral oscillator readings with mixed RSI signals. Recent corporate actions include dividend payments scheduled for 2026. The broader bond market faces pressure from rising Treasury yields, with the 10-year yield hitting levels not seen since 2007 according to MarketBeat on September 30, 2026.
The outlook remains cautious as high yield corporate bonds face headwinds from rising interest rates and inflationary pressures. Investment opportunities exist for income-focused investors through scheduled dividends, but risks include continued bond market volatility and economic uncertainty. HYG's performance will be closely tied to Federal Reserve policy and corporate credit conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
